- Home
- WINT vs NUAIW Comparison
WINT vs NUAIW Comparison
Compare WINT & NUAIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- NUAIW
- Stock Information
- Founded
- WINT 1992
- NUAIW N/A
- Country
- WINT United States
- NUAIW United States
- Employees
- WINT N/A
- NUAIW N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- NUAIW
- Sector
- WINT Health Care
- NUAIW
- Exchange
- WINT Nasdaq
- NUAIW Nasdaq
- Market Cap
- WINT 2.2M
- NUAIW 2.1M
- IPO Year
- WINT 1995
- NUAIW N/A
- Fundamental
- Price
- WINT $0.14
- NUAIW $0.08
- Analyst Decision
- WINT Hold
- NUAIW
- Analyst Count
- WINT 1
- NUAIW 0
- Target Price
- WINT $350.00
- NUAIW N/A
- AVG Volume (30 Days)
- WINT 5.2M
- NUAIW N/A
- Earning Date
- WINT 08-26-2025
- NUAIW N/A
- Dividend Yield
- WINT N/A
- NUAIW N/A
- EPS Growth
- WINT N/A
- NUAIW N/A
- EPS
- WINT N/A
- NUAIW N/A
- Revenue
- WINT N/A
- NUAIW N/A
- Revenue This Year
- WINT N/A
- NUAIW N/A
- Revenue Next Year
- WINT N/A
- NUAIW N/A
- P/E Ratio
- WINT N/A
- NUAIW N/A
- Revenue Growth
- WINT N/A
- NUAIW N/A
- 52 Week Low
- WINT $0.10
- NUAIW N/A
- 52 Week High
- WINT $662.00
- NUAIW N/A
- Technical
- Relative Strength Index (RSI)
- WINT 24.01
- NUAIW N/A
- Support Level
- WINT $0.45
- NUAIW N/A
- Resistance Level
- WINT $0.51
- NUAIW N/A
- Average True Range (ATR)
- WINT 0.08
- NUAIW 0.00
- MACD
- WINT -0.05
- NUAIW 0.00
- Stochastic Oscillator
- WINT 8.93
- NUAIW 0.00
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.